Adicet Bio
ACET
64 hedge funds and large institutions have $82.3M invested in Adicet Bio in 2024 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 16 increasing their positions, 23 reducing their positions, and 29 closing their positions.
6% more capital invested
Capital invested by funds: $77.4M → $82.3M (+$4.83M)
0.53% less ownership
Funds ownership: 4.87% → 4.33% (-0.53%)
26% less funds holding
Funds holding: 86 → 64 (-22)
30% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 23
67% less call options, than puts
Call options by funds: $6K | Put options by funds: $18K
76% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 29
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
+$1.11M |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$924K |
| 3 |
RC
RBF Capital
San Francisco,
California
|
+$323K |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$154K |
| 5 |
DC
Diametric Capital
Boston,
Massachusetts
|
+$154K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$2.33M |
| 2 |
RI
RTW Investments
New York
|
-$1.27M |
| 3 |
Morgan Stanley
New York
|
-$1.19M |
| 4 |
CAC
Cowen and Company
New York
|
-$970K |
| 5 |
OCA
Octagon Capital Advisors
New York
|
-$929K |
ACET Hedge Fund Activity: Q3 2024 in Review
64 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Adicet Bio (ACET) for Q3 2024, worth a combined $82.3M — up 6.2% from $77.4M a quarter earlier.
Sellers outnumbered buyers: 29 funds closed out of ACET and 7 opened new positions — a net loss of 22 holders — while 23 trimmed existing stakes and 16 added.
The largest buyer was Acadian Asset Management, adding an estimated $1.11M. The largest seller was Millennium Management, cutting an estimated $2.33M.
- 64 institutional investors held Adicet Bio (ACET) as of Q3 2024, down from 86 in Q2 2024.
- Funds reported $82.3M of Adicet Bio stock for Q3 2024, up 6.2% quarter-over-quarter.
- 7 funds opened new Adicet Bio positions in Q3 2024 and 29 closed out, a net change of -22 holders.
- The largest Adicet Bio buyer in Q3 2024 was Acadian Asset Management, an estimated $1.11M added.
- The largest Adicet Bio seller in Q3 2024 was Millennium Management, an estimated $2.33M sold.
Based on aggregated 13F filings for Q3 2024.